British HealthTech startup Laverock Therapeutics, a gene control company focused on the development of disease-responsive advanced therapies, announced the expansion of its Seed funding round, taking the total raised to more than €23.3 million.
The investment was led by Calculus Capital, with participation from existing investors Eli Lilly and Company, Mercia Ventures, Eos Advisory and Maven Capital Partners, and new investors Norcliffe Capital.
David Venables, CEO of Laverock, said: “The Laverock team has been busy over recent months, continuing to validate our technology platforms but also generating functional data for our therapeutic programmes. This new funding will enable us to continue this development, as well as forming partnerships and collaborations to integrate our technologies into partners’ therapeutic pipelines. I’d like to thank all our existing and new investors for their continued support.”
Founded in 2021, Laverock Therapeutics is innovating the development of disease-responsive advanced therapies through their programmable gene control technology. Their platform harnesses the cell’s natural regulatory mechanisms to deliver programmable and tunable gene control through recoded miRNAs. This reportedly enables the development of highly effective medicines with enhanced precision and improved safety profiles.
They are working to develop the next-generation of advanced therapies, both through their own pipeline – targeting oncology and genetic medicine – and through partnerships.
Laverock’s leadership team brings together experience in biotechnology, pharma, and academia.
The company has recently achieved platform development and validation and is transitioning to lead product selection, reporting positive functional data for both its primary T-cell and Macrophage programmes, demonstrating enhanced tumour control in haematological and solid tumour cancer models.
Laverock’s platform technologies provide the potential to transform the efficacy, precision and safety of advanced therapies, through implementation of its programmable, tunable and multiplex gene silencing approach.
Elizabeth Klein, Investment Director at Calculus, added: “We are delighted to continue our support for Laverock’s progress in pioneering a new era of programmable advanced therapies. This new data and expanded funding demonstrate the potential of Laverock’s technologies. We look forward to continuing our work with David and the team as they drive forward product development opportunities, as well as delivering value for our investors.”
To reflect Laverock’s recent progress, the company has updated its corporate identity, including the launch of a new website, to demonstrate the expansion of its platform technologies and facilitate an enhanced focus on partnering and outlicensing activities.
Read the orginal article: https://www.eu-startups.com/2025/06/london-based-startup-laverock-therapeutics-raises-over-e23-3-million-for-its-gene-control-tech/
